- Home
- BGMS vs SXTP Comparison
BGMS vs SXTP Comparison
Compare BGMS & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGMS | SXTP |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 4.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BGMS | SXTP |
|---|---|---|
| Price | $1.04 | $3.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.60 |
| AVG Volume (30 Days) | 146.0K | ★ 295.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $137.21 | $146.28 |
| Revenue Next Year | N/A | $24.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $0.34 |
| 52 Week High | $6.70 | $8.62 |
Technical Indicators
Market Signals| Indicator | BGMS | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 49.10 |
| Support Level | $0.98 | $3.02 |
| Resistance Level | $1.06 | $3.33 |
| Average True Range (ATR) | 0.13 | 0.42 |
| MACD | 0.02 | -0.24 |
| Stochastic Oscillator | 58.21 | 9.15 |
Price Performance
Historical ComparisonAbout BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.